Description of the hemodynamic and respiratory effects of hemoperfusion treatment with polymyxin B in patients with abdominal septic shock;Descripción de los efectos hemodinámicos y respiratorios del tratamiento mediante hemoperfusión con polimixina B en pacientes con shock séptico de origen abdominal

Revista Espanola de Anestesiologia y Reanimacion

Volumn 60, Issue 6, 2013, Pages 344-347

  Navarro, R ^a   Guerrero, M ^b   Gonzalez M ^b   Quecedo, L ^a   Garcia A ^b   Ramasco, F ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Hemoperfusion; Polymyxin; Sepsis; Septic shock

Indexed keywords

ANTIINFECTIVE AGENT; POLYMYXIN B;

ABDOMEN; ADULT; AGED; ARTICLE; BREATHING; DRUG EFFECT; HEMODYNAMICS; HEMOPERFUSION; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SEPTIC SHOCK;

ABDOMEN; ADULT; AGED; ANTI-BACTERIAL AGENTS; COMBINED MODALITY THERAPY; HEMODYNAMICS; HEMOPERFUSION; HUMANS; MIDDLE AGED; POLYMYXIN B; RESPIRATION; RETROSPECTIVE STUDIES; SHOCK, SEPTIC;

EID: 84881298464     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redar.2012.11.006     Document Type: Article

References (9)

1. Torrabadella P. Aspectos generales de la sepsis y el shock séptico: diagnóstico y epidemiología. Sepsis grave 2002, 1-20. Ediciones Experiencia, Barcelona. P. Torrabadella (Ed.).
2. Candel F.J., Martínez-Sagasti F., Borges M., Maseda E., Herrera-Gutiérrez M., Garnacho-Montero J., et al. La depuración de endotoxina como tratamiento coadyuvante en la sepsis grave por microorganismos gramnegativos. Rev Esp Quimioter 2010, 23:115-121.
3. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., et al. Surviving sepsis campaing: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327.
4. Marshall J.C., Foster D., Vincent J.L., Cook D.J., Cohen J., Dellinger R.P., et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004, 190:527-534.
5. Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Alvarez F., et al. A pilot-controlled study of a polymyxin B-inmobilized hemoperfusion cartridge in patients with severe sepsis secondary to intr-abdominal infection. Shock 2005, 23:400-405.
6. Cruz D.N., Perazella M.A., Bellomo R., de Cal M., Polanco N., Corradi V., et al. Effectiveness of polymyxin B-inmobilized fiber column in sepsis: a systematic review. Crit Care 2007, 11:R47.
7. Cruz D.N., Antonelli M., Fumagalli R., Foltran F., Brienza N., Donati A., et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009, 301:2445-2452.
8. Rachoin J.S., Foster D., Dellinger R.P. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES. Endotoxemia and endotoxin shock 2010, 111-118. Karger, Basel. C. Ronco, P. Piccinni, M.H. Rosner (Eds.).
9. Maynar J., Herrera M., Marti F., Sanchez-Izquierdo J.A., Martinez-Sagasti F., Fonseca F. Hemoperfusión with toraymyxin in patients with severe sepsis due to intestinal perforation. Inflamm Res 2007, 56(Supp):S238.